Development of cyclosporin A-loaded hyaluronic microsphere with enhanced oral bioavailability

International Journal of Pharmaceutics

Volumn 345, Issue 1-2, 2007, Pages 134-141

  Woo, Jong Soo ^a   Piao, Ming Guan ^a   Li, Dong Xun ^a   Ryu, Dong Sung ^a   Choi, Jun Young ^a   Kim, Jung Ae ^a   Kim, Jeong Hoon ^b   Jin, Sung Giu ^b   Kim, Dae Duk ^c   Lyoo, Won Seok ^a   Yong, Chul Soon ^a   Choi, Han Gon ^a  

^a Yeungnam University   (South Korea)

^b Dong A Pharmaceutical Company   (South Korea)

^c Seoul National University   (South Korea)

Author keywords

Bioavailability; Cyclosporin A; Microsphere; Sodium hyaluronate; Sodium lauryl sulfate; Spray drying

Indexed keywords

CYCLOSPORIN A; DODECYL SULFATE SODIUM; HYALURONIC ACID; MICROSPHERE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SPRAY DRYING;

ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHYSICAL; CYCLOSPORINE; DATA INTERPRETATION, STATISTICAL; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; HYALURONIC ACID; IMMUNOSUPPRESSIVE AGENTS; KINETICS; MALE; MICROSCOPY, ELECTRON, SCANNING; MICROSPHERES; PARTICLE SIZE; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY;

EID: 36048934949     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2007.08.050     Document Type: Article

References (45)

1. Aberturas M.R., Molpeceres J., Guzman M., and Garcia R. Development of a new cyclosporin formulation based on poly (caprolactone) microspheres. J. Microencapsul. 19 (2002) 61-72
2. Attama A.A., and Mpamaugo V.E. Pharmacodynamics of piroxicam from self-emulsifying lipospheres formulated with homolipids extracted from Capra hircus. Drug Deliv. 13 (2006) 133-137
3. Chacon M., Berges L., Molpeceres J., Aberturas M.R., and Guzman M. Optimized preparation of poly d,l (lactic-glycolic) microspheres and nanoparticles for oral administration. Int. J. Pharm. 141 (1996) 81-91
4. Chacon M., Molpeceres J., Berges L., Guzman M., and Aberturas M.R. Stability and freeze-drying of cyclosporine loaded poly (d,l lactide-glycolide) carriers. Eur. J. Pharm. Sci. 8 (1999) 99-107
5. Chen X.X., Young T.J., Sarkari M., Williams III R.O., and Johnston K.P. Preparation of cyclosporin A nanoparticles by evaporative precipitation into aqueous solution. Int. J. Pharm. 242 (2002) 3-14
6. Choi H.G., and Kim C.K. Application of dry elixir system to oriental traditional medicine: taste masking of peonjahwan by coated dry elixir. Arch. Pharm. Res. 23 (2000) 66-71
7. ®) l in organ transplantation. Drugs 61 (2001) 1957-2016
8. Drewe J., Beglinger C., and Kissel T. The absorption site of cyclosporin in the human gastrointestinal tract. Br. J. Clin. Pharmacol. 33 (1992) 39-43
9. Francis M.F., Lavoie L., Winnik F.M., and Leroux J.C. Solubilization of cyclosporin A in dextran-g-polyethyleneglycolalkyl ether polymeric micelles. Eur. J. Pharm. Biopharm. 56 (2003) 337-346
10. Gabrielsson J.L., and Weiner D.L. Methodology for pharmacokinetic/pharmacodynamic data analysis. Pharm. Sci. Technol. Today 2 (1999) 244-252
11. Gao Z.G., Choi H.G., Shin H.J., Park K.M., Lim S.J., Hwang K.J., and Kim C.K. Physicochemical characterization and evaluation of a microemulsion system for oral delivery of cyclosporin A. Int. J. Pharm. 161 (1998) 75-86
12. Gennery A.R., OSullivan J.J., Hasan A., Hamilton J.R.L., and Dark J.H. Changing cyclosporin A formulation: an analysis in paediatric cardiac transplant recipients. Pediatr. Transplant. 3 (1999) 215-218
13. Ghosh L.K., Ghosh N.C., Chatterjee M., and Gupta B.K. Product development studies on the tablet formulation of ibuprofen to improve bioavailability. Drug Dev. Ind. Pharm. 24 (1998) 473-477
14. Goa K.L., and Benfield P. Hyaluronic acid. A review of its pharmacology and use as a surgical aid in ophthalmology, and its therapeutic potential in joint disease and wound healing. Drugs 47 (1994) 536-566
15. Gref R.P., Quellec S.A., Calvo P., Dellacherie E., and Alonso M.J. Development and characterization of CyA-loaded poly (lactic acid)-poly (ethylene glycol) PEG micro- and nanoparticles. Comparison with conventional PLA particulate carriers. Eur. J. Pharm. Biopharm. 51 (2001) 111-118
16. Guzman M., Molpeceres J., Garcia F., Aberturas M.R., and Rodr'i{dotless}guez M. Formation and characterization of cyclosporine-loaded nanoparticles. J. Pharm. Sci. 82 (1993) 498-502
17. Huang S.L., Ling P.X., and Zhang T.M. Oral absorption of hyaluronic acid and phospholipids complexes in rats. World J. Gastroenterol. 13 (2007) 945-949
18. Ismailos G., Reppas C., Dressman J.B., and Macheras P. Unusual solubility behavior of cyclosporin A in aqueous media. J. Pharm. Pharmacol. 43 (1991) 287-289
19. Jederstrom G., Andersson A., Grasjo J., and Sjoholm I. Formulating insulin for oral administration: preparation of hyaluronan-insulin complex. Pharm. Res. 21 (2004) 2040-2047
20. Jederstrom G.G., Nordin A., Sjoholm I., and Andersson A. Blood glucose-lowering activity of a hyaluronan-insulin complex after oral administration to rats with diabetes. Diabetes Technol. Ther. 7 (2005) 948-957
21. Jouon N., Rinaudo M., Milas M., and Desbrieres J. Hydration of hyaluronic acid as a function of the counterion type and relative humidity. Carbohydr. Polym. 26 (1995) 69-73
22. Kaufmann J., Mohle K., Hofmann H.J., and Arnold K. Molecular dynamics study of hyaluronic acid in water. Theochem. J. Mol. Struct. 422 (1998) 109-121
23. Kawashima Y., Saito M., and Takenaka H. Improvement of solubility and dissolution rate of poorly water-soluble salicyclic acid by a spray drying technique. J. Pharm. Pharmacol. 27 (1975) 1-5
24. Khanfar M.S., Salem M.S., Najib N.M., and Pillai G.K. Dissolution behaviour of sustained release formulations of indomethacin with Eudragit RS. Acta. Pharm. Hung. 67 (1997) 235-239
25. Kim S.J., Choi H.K., and Lee Y.B. Pharmacokinetic and pharmacodynamic evaluation of cyclosporine A O/W-emulsion in rats. Int. J. Pharm. 249 (2002) 149-156
26. Kim S.J., Choi H.K., Suh S.P., and Lee Y.B. Pharmacokinetic and pharmacodynamic evaluation of cycloporin A O/W-emulsion and microsphere formulations in rabbits. Eur. J. Pharm. Sci. 15 (2002) 497-502
27. Kim C.K., Choi J.Y., Yoon Y.S., Gong J.P., Choi H.G., Kong J.Y., and Lee B.J. Preparation and evaluation of dry elixir for the enhancement of dissolution rate of poorly water-soluble drugs. Int. J. Pharm. 106 (1994) 25-32
28. Kim C.K., Ryu S.A., Park K.M., Lim S.J., and Hwang S.J. Preparation and physicochemical characterization of phase inverted water/oil microemulsion containing cyclosporin A. Int. J. Pharm. 147 (1997) 131-134
29. Lapcik L., De Smedt S., Demeester J., and Chabrecek P. Hyaluronan: preparation, structure, properties, and applications. Chem. Rev. 98 (1998) 2663-2684
30. Laurent T.C., Laurent U.B.G., and Fraser J.R.E. Functions of hyaluronan. Ann. Rheum. Dis. 54 (1995) 429-432
31. Lee S.W., Choi H.G., Lee M.K., Gao Z.G., Kim I.S., and Kim C.K. Trials of in situ-gelling and mucoadhesive acetaminophen liquid suppository in human subjects. Int. J. Pharm. 174 (1998) 201-207
32. Lee E.J., Lee S.W., Choi H.G., and Kim C.K. Bioavailability of cyclosporin A dispersed in sodium lauryl sulfate-dextrin based solid microspheres. Int. J. Pharm. 218 (2001) 125-131
33. Miyake K., Arima H., Irie T., Hirayama F., and Uekama K. Enhanced absorption of cyclosporin A by complexation with dimethyl-beta-cyclodextrin in bile duct-cannulated and -noncannulated rats. Biol. Pharm. Bull. 22 (1999) 66-72
34. Molpeceres J., Aberturas M.R., and Guzman M. Biodegradable nanoparticles as a delivery system for cyclosporine: preparation and characterization. J. Microencapsul. 17 (2000) 599-614
35. Piao M.G., Kim J.H., Kim J.O., Lyoo W.S., Lee M.H., Yong C.S., and Choi H.G. Enhanced oral bioavailability of piroxicam in rats by hyaluronate microspheres. Drug Dev. Ind. Pharm. 33 (2007) 485-491
36. Rasenack N., and Muller B.W. Dissolution rate enhancement by in situ micronization of poorly water-soluble drugs. Pharm. Res. 19 (2002) 1894-1900
37. Sajjadi H., Soheilian M., Ahmadieh M., Hussanein K., Parvin M., Azarmina M., Ehyaee V., and Amiransari B. Low dose cyclosporin-A therapy in Behc_et's disease. J. Ocul. Pharmacol. 10 (1994) 553-560
38. Society of Toxicology (SOT), 1999, Guiding Principles in the Use of Animals in Toxicology, www.toxicology.org/AI/FA/guidingprinciples.pdf.
39. Taylor N.E., Mark A.E., Vallat P., Brunne R.M., Testa B., and Van Gunteren W.F. Solvent dependent conformation and hydrogen bounding capacity of cyclosporin A: evidence from partition coefficient and molecular dynamics simulations. J. Med. Chem. 36 (1993) 3753-3764
40. Tejani A. Neoral: the microemulsion formulation. Pediatr. Transplant. 2 (1998) 85-86
41. Thomson A.W., and Neild G.H. Cyclosporin: use outside transplantation. Brit. Med. J. 302 (1991) 4-5
42. Tom J.C., Earl J.W., Willis N.S., Farquhar J.E., Nath C.E., Knight J.F., and Hodson E.M. Pharmacokenetics of cyclosporin in children with stable renal transplants. Pediatr. Nephrol. 15 (2000) 167-170
43. Tsuda Y., Ishida M., Suzuke E., and Sekiguchi K. Spray drying of Griseofulvin solution forming its solvate. Chem. Pharm. Bull. 36 (1988) 2193-2196
44. Ugazio E., Cavalli R., and Gasco M.R. Incorporation of cyclosporin A in solid lipid nanoparticles (SLN). Int. J. Pharm. 241 (2002) 341-344
45. Urata T., Arimori K., and Nakano H. Modification of release rates of cyclosporin A from polyl(l-lactic acid) microspheres by fatty acid esters and in-vivo evaluation of the microspheres. J. Control. Rel. 58 (1999) 133-141